CLDX
Celldex TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case is that the April financing removed a near-term capital constraint, while barzolvolimab keeps generating development momentum across multiple inflammatory indications and Phase 3 CSU enrollment finished ahead of guidance, preserving a potentially important 2026-2027 registration path [#8-K-2026-04-02] [#8-K-2026-02-25].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +12.5.
What can break
Biotech execution risk remains elevated around enrollment quality, data reproducibility across indications, regulatory interpretation, and eventual commercialization readiness for barzolvolimab.
Momentum
77
Value
41
Sentiment
42
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $34.00 · Bull $46.00 · Bear $24.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $57.53
Why
Momentum77 · Δ7d +12.5
Value41 · Δ7d -0.1
Sentiment42 · Δ7d +6.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
77
26% active weight
Current posture
7d trendImproving
Δ7d
+12.5
Δ21d
+37.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
42
34% active weight
Current posture
7d trendImproving
Δ7d
+6.7
Δ21d
-1.3
Why this grade
Composite grade C. Momentum 77.1 / Value 41.1 / Sentiment 42.3
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$2.77B
Beta
1.25
Shares Out
78.49M
P/E (TTM) · Derived
-9.1
P/S (TTM)
654.27
P/FCF (TTM) · Derived
-10.39
Rev YoY
-97.8%
EPS YoY
+45.9%
Gross Margin
-288.8%
Op Margin
-9855.4%
Net Debt
-$511.84M
Current Ratio
8.92
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology